# Arbor Biotechnologies

Arbor Biotechnologies is an other based in Cambridge, United States.

## Overview

- **Organization type:** other
- **Headquarters:** Cambridge, United States
- **Region:** North America
- **Address:** 20 Acorn Park Drive, Suite 500, Cambridge, MA 02140, United States
- **Founded:** 2016
- **Assets under management:** Undisclosed
- **Website:** www.arbor.bio
- **LinkedIn:** https://www.linkedin.com/company/arborbio

## Regulatory record

- **Reports private funds:** No

## About

At Arbor® Biotech, we develop genetic medicines through our discovery of programmable DNA editors to enable curative outcomes for patients.

## Sectors

- Biotech
- Gene Editing
- CRISPR
- Genetic Medicines

## People

- Devyn Smith — Chief Executive Officer
- Mat Pletcher — Chief Scientific Officer
- Don Haut — Chief Business Officer
- Feng Zhang — Co-founder and Scientific Advisory Board Chair

## Questions

### Who runs investment decisions at Arbor Biotechnologies?

Arbor is a private biotech company, so investment decisions are made by its board and management, led by CEO Devyn Smith. Key board members include Paul Meister (Chairman), Keith Crandell (Arch Venture Partners), and Mark Angelino (Third Rock Ventures) who represent major investors. The company has raised venture capital from Arch, Third Rock, and other top life sciences investors (per the firm's website).

### How does Arbor source proprietary deal flow?

Arbor generates its own pipeline through internal discovery of novel CRISPR systems — it does not primarily license editors from others. The company has built a portfolio of proprietary DNA editors covering over 90% of the human genome, which it then uses to develop targeted therapies for rare genetic diseases (per the firm).

### Does Arbor participate in fund commitments or only direct deals?

Arbor does not make investments; it raises capital from institutional investors to fund its internal R&D. The company has executed partnerships and licensing deals with larger pharma companies like Vertex and Chiesi, which provide non-dilutive funding and collaboration support.

### What investment stages does Arbor typically target?

Arbor is not an investor; it is a company that itself progresses from discovery through clinical development. Its most advanced candidate, ABO-101, reached IND clearance and regulatory approvals in 2025 — representing a late-stage development milestone for a biotech.

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/arbor-biotechnologies

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology